Company Overview
About Amplitude Vascular Systems
Amplitude Vascular Systems (AVS) is a medical device company headquartered in Fremont, California, founded to develop next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral artery disease (PAD). The company''s flagship product, the Pulse IVL system, delivers high-frequency pulsatile pressure waves through a catheter-based device to fracture calcium deposits in arterial walls — restoring vessel compliance and improving blood flow in patients with calcified, obstructed arteries in the legs, below-the-knee vessels, and other peripheral vascular territories. Calcified PAD is a significant and growing clinical problem, particularly in diabetic patients and the aging population, where conventional balloon angioplasty and stenting are less effective due to hard, calcified lesion morphology.
Business Model & Competitive Advantage
AVS raised over $75M in total funding to support device development and clinical trials, competing in an IVL market pioneered by Shockwave Medical (acquired by Johnson & Johnson for $13.1B in 2024). While Shockwave focused on coronary and peripheral IVL with its S-IVL and C-IVL systems, AVS is developing a differentiated IVL approach targeting specific clinical niches in peripheral vascular intervention — including below-the-knee (BTK) territories that Shockwave''s current coronary-focused system does not address. The Pulse IVL system is designed to deliver controlled pressure waves with a distinct frequency and energy profile from Shockwave''s sonic pressure wave approach.
Competitive Landscape 2025–2026
AVS is in active clinical development stages, with ongoing feasibility and pivotal trials supporting a potential FDA clearance pathway for its Pulse IVL system. The company represents a next-generation challenger in the IVL market — entering a space that Shockwave''s acquisition by J&J has validated at massive scale, while pursuing differentiated device technology and peripheral vascular indications where clinical need remains high and competitive alternatives are limited.
Key Differentiators
Emerging Innovator
Amplitude Vascular Systems is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Amplitude Vascular Systems with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Amplitude Vascular Systems? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Amplitude Vascular Systems Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Amplitude Vascular Systems vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →